Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in MSS Metastatic Colorectal Cancer
NCT03912857Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03912857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912857.